The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...

Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...

Nektar Therapeutics is selling off its only manufacturing facility as well as its reagent business to private equity firm Ampersand Capital Partners for $90 million. In the deal, which is ...

(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...

The letter ampersand, usually known as '&', was thought to be the alphabet's final letter (27th). The letter was once pronounced as 'and', much as the symbol & stands for today. But saying and ...

--(BUSINESS WIRE)--Viamedia, the country’s largest independent advertising digital and linear rep firm, today announced the appointment of Ken Little, former Chief Operating Officer of Ampersand ...

SARANAC LAKE — Ampersand Biosciences and Trudeau Institute have been awarded more than $1 million to study infectious diseases. A $1,084,824 Phase II Small Business Innovative Research grant ...

Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.

Bastille’s Dan Smith has just released & (Ampersand) – an intimate record he started after the band returned from touring last year. Here, he talks us through the unique process ...

BOSTON, Oct. 31, 2024 /PRNewswire/ -- For the third consecutive year, Ampersand Capital Partners has been named to Inc.'s 2024 Founder-Friendly Investors list, which honors the private equity and ...